FI51936C - A process for the preparation of therapeutically useful 3,4-dihydronaphthalenoxyoxy-2-hydroxypropylamines and their acid addition salts. - Google Patents

A process for the preparation of therapeutically useful 3,4-dihydronaphthalenoxyoxy-2-hydroxypropylamines and their acid addition salts.

Info

Publication number
FI51936C
FI51936C FI692717A FI271769A FI51936C FI 51936 C FI51936 C FI 51936C FI 692717 A FI692717 A FI 692717A FI 271769 A FI271769 A FI 271769A FI 51936 C FI51936 C FI 51936C
Authority
FI
Finland
Prior art keywords
dihydronaphthalenoxyoxy
hydroxypropylamines
preparation
acid addition
addition salts
Prior art date
Application number
FI692717A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI51936B (en
Inventor
Jr John Shavel
Sheldon Farber
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to FI762870A priority Critical patent/FI762870A/fi
Application granted granted Critical
Publication of FI51936B publication Critical patent/FI51936B/fi
Publication of FI51936C publication Critical patent/FI51936C/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/38—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C07D303/26—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds having one or more free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
FI692717A 1968-09-23 1969-09-23 A process for the preparation of therapeutically useful 3,4-dihydronaphthalenoxyoxy-2-hydroxypropylamines and their acid addition salts. FI51936C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI762870A FI762870A (en) 1968-09-23 1976-10-08

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76185768A 1968-09-23 1968-09-23

Publications (2)

Publication Number Publication Date
FI51936B FI51936B (en) 1977-01-31
FI51936C true FI51936C (en) 1977-05-10

Family

ID=25063434

Family Applications (1)

Application Number Title Priority Date Filing Date
FI692717A FI51936C (en) 1968-09-23 1969-09-23 A process for the preparation of therapeutically useful 3,4-dihydronaphthalenoxyoxy-2-hydroxypropylamines and their acid addition salts.

Country Status (15)

Country Link
US (1) US3641152A (en)
JP (1) JPS4843734B1 (en)
BE (1) BE739195A (en)
CH (1) CH525183A (en)
DE (2) DE1967162C3 (en)
DK (2) DK125588B (en)
ES (1) ES371737A1 (en)
FI (1) FI51936C (en)
FR (1) FR2018626B1 (en)
GB (1) GB1223527A (en)
IT (1) IT1033032B (en)
NL (1) NL139166B (en)
NO (1) NO128869B (en)
SE (1) SE362414B (en)
ZA (1) ZA695648B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE755071A (en) * 1969-09-17 1971-02-22 Warner Lambert Pharmaceutical METHOD FOR RESOLVING DL-5- / 3- (TERBUTYLAMINO) -2- HYDROXY-PROPOXY / -3,4-DIHYDRO-1 (2H) NAPHTHALENONE
US3959486A (en) * 1970-05-27 1976-05-25 Imperial Chemical Industries Limited Method for producing β-adrenergic blockage with alkanolamine derivatives
DE2130393C3 (en) * 1970-06-22 1981-02-26 E.R. Squibb & Sons Inc., New York, N.Y. (V.St.A.) 6,7-dihydroxy -5,6,7,8-tetrahydronaphthyloxyaminopropanols and their salts with acids and their use in combating heart disease
FR2119843B1 (en) * 1970-12-28 1974-03-22 Laroche Navarro Labo
JPS5122737Y2 (en) * 1972-12-30 1976-06-11
US3966749A (en) * 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
GB1493848A (en) * 1975-07-24 1977-11-30 Beecham Group Ltd Aryltetralins
CH621330A5 (en) * 1976-05-14 1981-01-30 Sandoz Ag
DE2810869A1 (en) * 1977-03-24 1978-09-28 Sandoz Ag 3-AMINO-2-HYDROXYPROPOXY DERIVATIVES, THEIR PRODUCTION AND USE
US4176183A (en) * 1977-05-02 1979-11-27 Merck & Co., Inc. Novel naphthyridines
US4270005A (en) * 1977-11-14 1981-05-26 Pfizer Inc. 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor
CH641147A5 (en) * 1979-01-17 1984-02-15 Sandoz Ag 3-AMINO-2-HYDROXYPROPOXYARYL DERIVATIVE, ITS PREPARATION AND REMEDIES CONTAINING THEREOF.
DE2943406A1 (en) * 1979-10-26 1981-05-07 Basf Ag, 6700 Ludwigshafen AMINO DERIVATIVES OF 2-METHYL-5- (2-HYDROXYSTYRYL) -1,3,4-THIADIAZOL
FR2507181A1 (en) 1981-06-05 1982-12-10 Sanofi Sa NOVEL ETHERS OF PHENOL ACTIVE ON THE CARDIOVASCULAR SYSTEM, PROCESS FOR PREPARING THEM AND USE THEREOF IN MEDICAMENTS
SE8801518D0 (en) * 1988-04-22 1988-04-22 Astra Pharma Prod A NOVEL PROCESS
US5225565A (en) * 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
ES2065278B1 (en) * 1993-06-24 1995-09-01 Medichem Sa LEVOBUNOLOL ENANTIOSELECTIVE PROCEDURE FOR OBTAINING.
AU7905001A (en) * 2000-07-27 2002-02-13 Pharmacia Corp Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1023214A (en) * 1962-12-17 1966-03-23 Ici Ltd Carbocyclic hydroxyamines

Also Published As

Publication number Publication date
ZA695648B (en) 1971-03-31
DE1948144C3 (en) 1980-01-17
GB1223527A (en) 1971-02-24
DE1948144B2 (en) 1979-05-03
JPS4843734B1 (en) 1973-12-20
FR2018626B1 (en) 1973-06-08
DK125588B (en) 1973-03-12
IT1033032B (en) 1979-07-10
ES371737A1 (en) 1972-03-16
US3641152A (en) 1972-02-08
FR2018626A1 (en) 1970-06-26
DK128536B (en) 1974-05-20
DE1967162C3 (en) 1981-03-19
NL6914077A (en) 1970-03-25
DE1948144A1 (en) 1970-03-26
BE739195A (en) 1970-03-23
DE1967162B1 (en) 1980-07-31
NO128869B (en) 1974-01-21
NL139166B (en) 1973-06-15
FI51936B (en) 1977-01-31
SE362414B (en) 1973-12-10
CH525183A (en) 1972-07-15

Similar Documents

Publication Publication Date Title
FI48731C (en) A process for the preparation of therapeutically useful 1-aminoalkyl-substituted phthalans and isochromanes and their acid addition salts.
FI51190C (en) Process for the preparation of therapeutically active, in particular N- (3,4,5-trimethoxy-cinnamoyl) -piperazine derivatives of the coronadilator.
FI51936C (en) A process for the preparation of therapeutically useful 3,4-dihydronaphthalenoxyoxy-2-hydroxypropylamines and their acid addition salts.
FI51350C (en) Process for the preparation of urinary excretion-promoting 6-sulfamyl-1,2,3,4-tetrahydro-4-quinazolinones and their salts.
FI52339C (en) A process for preparing therapeutically active 1,4-dihydropyridine derivatives.
CH546788A (en) PROCESS FOR PREPARING ANTI-INFLAMMATORY AGENTS.
FI49977C (en) Process for the preparation of therapeutically useful 3-alkoxythianaphthene-2-carboxamides and their 1,1-dioxides
FI52338C (en) Process for the preparation of therapeutically useful 1,2,3,6-tetrahydropyridine derivatives and their acid addition salts.
FI49720C (en) Process for the preparation of therapeutically active 2-methyl-3-carboxylic acid amidoquinoxaline di-N-oxides (1,4).
FI52715C (en) Process for the preparation of therapeutically useful vitamin A acid amides.
FI48728C (en) Analogous process for the preparation of therapeutically useful phenylacetic acid derivatives.
FI49827C (en) Process for the preparation of therapeutically active substituted 3-hydroxymethylisoquinolines.
IL36435A (en) Methyl 7-o-methyl-6,8-dideoxy-6-(trans-1-methyl-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-l-threo-alpha-d-galacto-octopyranoside,the acid addition salts thereof and the production of these
FI51176C (en) Process for the preparation of therapeutically useful 4-aryl-1- (4,4-diarylbutyl) -4-hydroxypiperidines and their acid addition salts.
FI51479C (en) A process for preparing a therapeutically useful 3,3-disubstituted hexahydro-1H-azepine compound.
FI49718C (en) Process for the preparation of therapeutically active 2-halomethyl-3-carboxylic acid amidoquinoxaline di-N-oxides- (1,4).
FI49166C (en) Process for the preparation of a beta-stimulating 6,7-diacyloxy-tetrahydroisoquinoline compound and its pharmaceutically acceptable acid addition salt.
IL31910A0 (en) Indenopyridines,their acid addition salts,and the production thereof
FI51349C (en) Process for the preparation of therapeutically active N-substituted 6,7-benzomorphans.
BR7105511D0 (en) PROCESS FOR THE PREPARATION OF DERIVATIVES 1,4 BENZODIAZEPINICS
FI49417C (en) Process for the preparation of pharmacologically active 2,3-dihydro-benz ofuran-2-carboxylic acids.
FI45450C (en) A process for the preparation of therapeutically useful phentiazine derivatives and their salts
FI45175C (en) Process for the preparation of 18-methyl-19-nor-17alpha-hydroxy-progesterones and their 17alpha-esters.
FI45555C (en) A process for the preparation of therapeutically useful strophantidine-type cardiac lycoside derivatives.
BR7106561D0 (en) PROCESS FOR THE PREPARATION OF 1 DINOPHOSPHONIC AMINOALKANIC-1,1 ACIDS